A Provisional Agreement between AbbVie and Pharmac will see the price of Humira Injections (all 3 presentations) reduce from $1799.92 ex manufacturer to $1599.96 with effect in the Pharmaceutical Schedule from 1 January 2016 if agreed by Pharmac Board.

In addition to the price reduction there will be a Confidential Rebate applied and Subsidy & Delisting Protection until 30 June 2019.

Please note with effect immediately ProPharma /PWR will NOT ACCEPT CREDIT RETURNS for any presentation of Humira Injection.

Our actions are based on this Provisional Agreement being confirmed and in place for 1 January 2016.

About The Author